The Go-To Resource for Imaging Professionals

Magazine Blog

ICE MAGAZINE

The NEW ICE Magazine will be your go to source for all things IMAGING!

Dr. Michelle White Named Mercy Ships CEO

Dr. Michelle White Named Mercy Ships CEO

Mercy Ships, a global nonprofit organization that delivers life-changing surgeries and medical care to underserved communities by operating fully volunteer staffed hospital ships, is pleased to announce the appointment of Dr. Michelle White, MB ChB, PhD, DCH, FRCA, as its new Chief Executive Officer.

Updated Tempus Pixel Device Receives FDA Special 510(k) Clearance

Updated Tempus Pixel Device Receives FDA Special 510(k) Clearance

Tempus AI Inc., a technology company leading the adoption of AI to advance precision medicine, has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis.

AI-enabled Voluson Performance Ultrasound Announced 

AI-enabled Voluson Performance Ultrasound Announced 

GE HealthCare recently announced the launch of the Voluson Performance series, the latest addition to its women’s health ultrasound portfolio. Designed to deliver detailed imaging and simplify workflow with artificial intelligence (AI) and automation tools, the new Voluson Performance 18 and 16 offers clinicians modern, innovative technology to assist with efficient care across a wide range of applications, a press release states. 

FDA Accepts Proposal for Reasonably Likely Surrogate Endpoint for ‘MASH’ All-Cause Mortality or Liver-Related Events

FDA Accepts Proposal for Reasonably Likely Surrogate Endpoint for ‘MASH’ All-Cause Mortality or Liver-Related Events

FDA’s Center for Drug Evaluation and Research, Office of New Drugs has accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (scarring).

ICE is the community that directly links nearly 9,000 imaging professionals and administrators. Each issue contains insightful and relevant content ranging from technological advances to new tools to professional development.

© 2026 ICE Magazine. Designed by MD Publishing.